Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:ITCINYSE:RDYNASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$20.92+1.4%$20.45$17.24▼$30.41$13.87B1.071.05 million shs122,731 shsITCIIntra-Cellular Therapies$131.87$131.22$64.09▼$131.98$14.05B0.691.46 million shsN/ARDYDr. Reddy's Laboratories$13.85-0.7%$13.18$12.26▼$16.89$11.56B0.511.46 million shs161,747 shsZLABZai Lab$31.18-3.9%$33.32$15.67▼$39.77$3.44B1.09852,908 shs209,479 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S+0.19%+2.79%+3.67%+5.36%-26.71%ITCIIntra-Cellular Therapies0.00%0.00%+0.05%+3.83%+80.00%RDYDr. Reddy's Laboratories+1.01%+1.97%+5.72%+3.16%-6.44%ZLABZai Lab+1.34%+9.16%-13.03%+21.55%+103.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S4.4341 of 5 stars4.35.00.00.03.40.03.1ITCIIntra-Cellular Therapies2.286 of 5 stars1.13.00.04.51.11.70.6RDYDr. Reddy's Laboratories1.8567 of 5 stars2.32.01.70.03.40.01.3ZLABZai Lab2.1682 of 5 stars3.41.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.69Moderate Buy$39.1787.19% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideRDYDr. Reddy's Laboratories 2.50Moderate Buy$17.0022.79% UpsideZLABZai Lab 2.75Moderate Buy$47.3751.91% UpsideCurrent Analyst Ratings BreakdownLatest ZLAB, ITCI, GMAB, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.004/1/2025GMABGenmab A/SSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform ➝ Underperform3/27/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/13/2025ZLABZai LabJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $51.003/11/2025GMABGenmab A/STruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $45.003/11/2025GMABGenmab A/SWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/7/2025ZLABZai LabScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/4/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025ZLABZai LabBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$29.00 ➝ $36.102/24/2025ITCIIntra-Cellular TherapiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$21.53B0.64$1.41 per share14.80$8.04 per share2.60ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44RDYDr. Reddy's Laboratories$311.31B0.04$1.04 per share13.25$4.50 per share3.08ZLABZai Lab$398.99M8.61N/AN/A$8.05 per share3.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7412.0411.752.6536.30%16.78%13.79%5/8/2025 (Estimated)ITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)RDYDr. Reddy's Laboratories$668M$0.6322.0516.88N/A17.25%17.87%12.32%5/6/2025 (Estimated)ZLABZai Lab-$334.62M-$2.59N/AN/AN/A-76.14%-36.97%-27.10%5/8/2025 (Estimated)Latest ZLAB, ITCI, GMAB, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.26N/AN/AN/A$5.17 billionN/A5/8/2025Q1 2025ZLABZai Lab-$0.33N/AN/AN/A$118.40 millionN/A5/6/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20N/AN/AN/A$83.70 billionN/A2/27/2025Q4 2024ZLABZai Lab-$0.61-$0.80-$0.19-$0.80$110.15 million$109.07 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/12/2025Q4 2024GMABGenmab A/S$0.28$0.57+$0.29$0.85$884.02 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.080.58%N/A12.70%N/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.255.24ITCIIntra-Cellular TherapiesN/A7.667.51RDYDr. Reddy's Laboratories0.021.921.38ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%ITCIIntra-Cellular Therapies92.33%RDYDr. Reddy's Laboratories3.85%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%ITCIIntra-Cellular Therapies2.60%RDYDr. Reddy's Laboratories2.00%ZLABZai Lab13.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S1,660661.97 million651.58 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableRDYDr. Reddy's Laboratories24,800834.77 million818.05 millionOptionableZLABZai Lab1,950110.13 million94.24 millionOptionableZLAB, ITCI, GMAB, and RDY HeadlinesRecent News About These CompaniesLegal & General Group Plc Reduces Holdings in Zai Lab Limited (NASDAQ:ZLAB)April 27 at 3:45 AM | marketbeat.comZai Lab presents data from studies evaluating two oncology therapiesApril 26 at 10:38 AM | markets.businessinsider.comXTX Topco Ltd Has $353,000 Position in Zai Lab Limited (NASDAQ:ZLAB)April 26 at 4:14 AM | marketbeat.comZai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025April 25, 2025 | businesswire.comMarshall Wace LLP Acquires Shares of 288,992 Zai Lab Limited (NASDAQ:ZLAB)April 25, 2025 | marketbeat.comTownsquare Capital LLC Invests $243,000 in Zai Lab Limited (NASDAQ:ZLAB)April 25, 2025 | marketbeat.comCantor Fitzgerald Reduces Earnings Estimates for Zai LabApril 25, 2025 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?April 24, 2025 | marketbeat.comEversept Partners LP Has $2.70 Million Stock Position in Zai Lab Limited (NASDAQ:ZLAB)April 24, 2025 | marketbeat.comZai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual MeetingApril 23, 2025 | finance.yahoo.comRock Springs Capital Management LP Decreases Stock Position in Zai Lab Limited (NASDAQ:ZLAB)April 23, 2025 | marketbeat.comB Group Inc. Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB)April 23, 2025 | marketbeat.comCapital International Investors Purchases 120,000 Shares of Zai Lab Limited (NASDAQ:ZLAB)April 23, 2025 | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Position Boosted by Renaissance Technologies LLCApril 22, 2025 | marketbeat.comZai Lab announces China NMPA acceptance of repotrectinib sNDAApril 21, 2025 | markets.businessinsider.comZai Lab Flat as China Okays ApplicationApril 21, 2025 | baystreet.caScotiabank Keeps Their Buy Rating on Zai Lab (ZLAB)April 21, 2025 | markets.businessinsider.comZai Lab gets China's acceptance for label expansion of repotrectinibApril 21, 2025 | msn.comZai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid TumorsApril 21, 2025 | businesswire.comJPMorgan Chase & Co. Buys 23,510 Shares of Zai Lab Limited (NASDAQ:ZLAB)April 21, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Trading Down 6.1% - Here's What HappenedApril 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZLAB, ITCI, GMAB, and RDY Company DescriptionsGenmab A/S NASDAQ:GMAB$20.92 +0.29 (+1.42%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Dr. Reddy's Laboratories NYSE:RDY$13.84 -0.10 (-0.68%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Zai Lab NASDAQ:ZLAB$31.18 -1.25 (-3.85%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Kroger: This Must-Own Staples Stock Thrives in Every Market 3M Stock: 4 Compelling Reasons to Buy, 1 Big Reason to Pass Disney: The Compelling Case for Buying Now Before They Scale Up Southwest Airlines CEO Calls Recession, Why Option Traders Jumped Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
